Because semaglutide slows digestion, oral medications may sometimes take longer to be absorbed into the bloodstream
A phase 2 trial of semaglutide 2.4 mg in 71 cirrhotic patients confirmed an acceptable safety profile without significant decompensation events, although the primary histological endpoint was not met, possibly due to the limited ability of antifibrotic remodeling to achieve biopsy-detectable fibrosis stage improvement in established cirrhosis over 48 weeks [46]
[3] [4] With retatrutide producing pronounced weight loss in early trials, questions about whether it carries a similar risk are understandable and clinically relevant
In this uncertain world, that GLP-1s are going to exert a larger impact on eating habits in the future is as sure of a bet as any at the moment
Hy cn thn vi cc sn phm gi, km cht lng trn th trng
Conversations that Count: ART for People Living with HIV Available for free access, this CPE podcast episode offers actionable steps to fostering trust and patient ownership throughout the antiretroviral therapy (ART) journey for people living with HIV